We receives advance assurance for EIS status in the United Kingdom
post-template-default,single,single-post,postid-10554,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution receives letter of support from Asthma UK

Bedford, UK, June 7th, 2019

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today received a letter of support from Asthma UK, the charity dedicated to improving the health and well-being of the 5.4 million people in the UK whose lives are affected by asthma.

The letter was provided following a meeting with senior staff of the charity, and states: “Asthma UK welcomes your proposal, which seeks to establish a novel approach to remove triggers of asthma by targeting house dust mites through development of a biological control agent. People with asthma have more sensitive airways than people without asthma, which means they are more likely to react to triggers. Triggers are anything which sets off asthma symptoms, and people can have multiple triggers, ranging from cold viruses to pollen. House dust mites are a common problem for people with asthma, and in our Annual Asthma Survey 2018 64% of respondents stated that dust triggered their asthma symptoms.”

The letter goes on to say that: “Asthma UK appreciates that your proposal aims to find a novel way to rid the home of house dust mites, as this may be beneficial for people with asthma – removing possible problematic triggers and improving overall quality of life.”

Dr. David Harper, Evolution’s CEO, said: “It is extremely encouraging to receive such a statement of support from the leading charity dedicated to improving the lives of asthmatics in the UK.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document and the video interviewed referenced herein contain certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email: pr@evolutionbiotech.com
Website: www.evolutionbiotech.com

No Comments

Sorry, the comment form is closed at this time.